LGI1 and encephalitis: The first-line efficacy rates of anti-NMDAR encephalitis and anti-GABABR encephalitis were relatively low at 70.2% and 70%, respectively, and the first-line efficacy rates of anti-LGI1 encephalitis and anti-CASPR2 encephalitis were 92.3% and 83.3%, respectively.